Literature DB >> 23399714

Abnormal aldosterone physiology and cardiometabolic risk factors.

Anand Vaidya1, Patricia C Underwood, Paul N Hopkins, Xavier Jeunemaitre, Claudio Ferri, Gordon H Williams, Gail K Adler.   

Abstract

Abnormal aldosterone physiology has been implicated in the pathogenesis of cardiometabolic diseases. Single aldosterone measurements capture only a limited range of aldosterone physiology. New methods of characterizing aldosterone physiology may provide a more comprehensive understanding of its relationship with cardiometabolic disease. We evaluated whether novel indices of aldosterone responses to dietary sodium modulation, the sodium-modulated aldosterone suppression-stimulation index (SASSI for serum and SAUSSI for urine), could predict cardiometabolic risk factors. We performed cross-sectional analyses on 539 subjects studied on liberal and restricted sodium diets with serum and urinary aldosterone measurements. SASSI and SAUSSI were calculated as the ratio of aldosterone on liberal (maximally suppressed aldosterone) to the aldosterone on restricted (stimulated aldosterone) diets and associated with risk factors using adjusted regression models. Cardiometabolic risk factors associated with either impaired suppression of aldosterone on liberal diet, or impaired stimulation on restricted diet, or both; in all of these individual cases, these risk factors associated with higher SASSI or SAUSSI. In the context of abnormalities that constitute the metabolic syndrome, there was a strong positive association between the number of metabolic syndrome components (0-4) and both SASSI and SAUSSI (P<0.0001) that was independent of known aldosterone secretagogues (angiotensin II, corticotropin, potassium). SASSI and SAUSSI exhibited a high sensitivity in detecting normal individuals with zero metabolic syndrome components (86% for SASSI and 83% for SAUSSI). Assessing the physiological range of aldosterone responses may provide greater insights into adrenal pathophysiology. Dysregulated aldosterone physiology may contribute to, or result from, early cardiometabolic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399714      PMCID: PMC3615445          DOI: 10.1161/HYPERTENSIONAHA.111.00662

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  39 in total

Review 1.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects.

Authors:  A Hannemann; H Wallaschofski; J Lüdemann; H Völzke; M R Markus; R Rettig; U Lendeckel; M Reincke; S B Felix; K Empen; M Nauck; M Dörr
Journal:  Atherosclerosis       Date:  2011-09-16       Impact factor: 5.162

3.  Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.

Authors:  Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

4.  Insulin resistance in hypertensives: effect of salt sensitivity, renin status and sodium intake.

Authors:  A Raji; G H Williams; X Jeunemaitre; P N Hopkins; S C Hunt; N K Hollenberg; E W Seely
Journal:  J Hypertens       Date:  2001-01       Impact factor: 4.844

5.  The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men.

Authors:  Anand Vaidya; John P Forman; Patricia C Underwood; Paul N Hopkins; Gordon H Williams; Luminita H Pojoga; Jonathan S Williams
Journal:  Eur J Endocrinol       Date:  2011-03-14       Impact factor: 6.664

6.  Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans.

Authors:  I S Okosun; Y Liao; C N Rotimi; T E Prewitt; R S Cooper
Journal:  Ann Epidemiol       Date:  2000-07       Impact factor: 3.797

7.  Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.

Authors:  Ana M Briones; Aurelie Nguyen Dinh Cat; Glaucia E Callera; Alvaro Yogi; Dylan Burger; Ying He; Jose W Corrêa; Anne Marie Gagnon; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Alexander Sorisky; Teik Chye Ooi; Marcel Ruzicka; Kevin D Burns; Rhian M Touyz
Journal:  Hypertension       Date:  2012-04-09       Impact factor: 10.190

8.  A comparison of the prevalence of the metabolic syndrome using two proposed definitions.

Authors:  Earl S Ford; Wayne H Giles
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.

Authors:  Katie Ayers; Loretta M Byrne; Anthony DeMatteo; Nancy J Brown
Journal:  Hypertension       Date:  2012-02-21       Impact factor: 10.190

10.  Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus.

Authors:  Patricia C Underwood; Bindu Chamarthi; Jonathan S Williams; Anand Vaidya; Rajesh Garg; Gail K Adler; Marissa P Grotzke; Gitana Staskus; Devendra Wadwekar; Paul N Hopkins; Claudio Ferri; Anthony McCall; Donald McClain; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-08-03       Impact factor: 5.958

View more
  32 in total

Review 1.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 2.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 3.  Cortisol dysregulation in obesity-related metabolic disorders.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

Review 4.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 5.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

6.  A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics.

Authors:  Rene Baudrand; Mark O Goodarzi; Anand Vaidya; Patricia C Underwood; Jonathan S Williams; Xavier Jeunemaitre; Paul N Hopkins; Nancy Brown; Benjamin A Raby; Jessica Lasky-Su; Gail K Adler; Jinrui Cui; Xiuqing Guo; Kent D Taylor; Yii-Der I Chen; Anny Xiang; Leslie J Raffel; Thomas A Buchanan; Jerome I Rotter; Gordon H Williams; Luminita H Pojoga
Journal:  Metabolism       Date:  2015-09-12       Impact factor: 8.694

7.  Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects.

Authors:  Rene Baudrand; Luminita H Pojoga; Anand Vaidya; Amanda E Garza; Paul A Vöhringer; Xavier Jeunemaitre; Paul N Hopkins; Tham M Yao; Jonathan Williams; Gail K Adler; Gordon H Williams
Journal:  Circulation       Date:  2015-10-02       Impact factor: 29.690

Review 8.  Mechanisms of altered renal sodium handling in age-related hypertension.

Authors:  Alissa A Frame; Richard D Wainford
Journal:  Am J Physiol Renal Physiol       Date:  2018-02-14

9.  Dysregulated aldosterone secretion in persons of African descent with endothelin-1 gene variants.

Authors:  Jia W Tan; Tina Gupta; Worapaka Manosroi; Tham M Yao; Paul N Hopkins; Jonathan S Williams; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  JCI Insight       Date:  2017-12-07

Review 10.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.